Ariad Pharmaceuticals presented data from an ongoing clinical trial testing brigatinib, an investigational treatment for patients with ALK+ non-small cell lung cancer and other malignancies.
The results were presented at the 6th European Lung Cancer Conference (ELCC) in Geneva, Switzerland. Ariad is focused on the treatment of various forms of chronic and acute leukemia, lung cancer, and other difficult-to-treat orphan cancers.
The primary endpoint of the Phase 1/2 trial was to assess patients’ overall response rate to the treatment, while the secondary endpoints included safety and tolerability, pharmacokinetic parameters, progression free survival, and overall survival.
The trial revealed anti-tumor activity in the 70 evaluable ALK+ NSCLC patients with prior crizotinib therapy who were treated with brigatinib in the study. The median progression-free survival (PFS) of these patients was found to be 13.4 months.
Moreover, tumor shrinkage was detected in all enrolled ALK+ NSCLC patients, and in 25 patients, lesion was reduced completely.
The most frequent treatment-related adverse effects included nausea (52 percent), fatigue (42 percent), diarrhea (40 percent), headache (33 percent), and cough (32 percent).